Explainable time-to-progression predictions in multiple sclerosis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
D'hondt Robbe, Dedja Klest, Aerts Sofie, Van Wijmeersch Bart, Kalincik Tomas, Reddel Stephen, Havrdova Eva Kubala, Lugaresi Alessandra, Weinstock-Guttman Bianca, Mrabet Saloua, Lalive Patrice, Kermode Allan G, Ozakbas Serkan, Patti Francesco, Prat Alexandre, Tomassini Valentina, Roos Izanne, Alroughani Raed, Gerlach Oliver, Khoury Samia J, van Pesch Vincent, Sá Maria José, Prevost Julie, Spitaleri Daniele, McCombe Pamela, Solaro Claudio, van der Walt Anneke, Butzkueven Helmut, Laureys Guy, Sánchez-Menoyo José Luis, de Gans Koen, Al-Asmi Abdullah, Deri Norma, Csepany Tunde, Al-Harbi Talal, Carroll William M, Rozsa Csilla, Singhal Bhim, Hardy Todd A, Ramanathan Sudarshini, Peeters Liesbet, Vens Celine, MSBase Study Group
Аннотация
METHODS: A preprocessed subset of 29,201 patients of the international data registry MSBase was used. Disability was assessed in terms of the Expanded Disability Status Scale (EDSS). We predict the time to significant and confirmed disability progression using random survival forests, a machine learning model for survival analysis. Performance is evaluated on a time-dependent area under the receiver operating characteristic and the precision-recall curves. Importantly, predictions are then explained using SHAP and Bellatrex, two explainability toolboxes, and lead to both global (population-wide) as well as local (patient visit-specific) insights.
RESULTS: On the task of predicting progression in 2 years, the random survival forest achieves state-of-the-art performance, comparable to previous work employing a random forest. However, here the random survival forest has the added advantage of being able to predict progression over a longer time horizon, with AUROC >60% for the first 10 years after baseline. Explainability techniques further validated the model by extracting clinically valid insights from the predictions made by the model. For example, a clear decline in the per-visit probability of progression is observed in more recent years since 2012, likely reflecting globally increasing use of more effective MS therapies.
CONCLUSION: The binary classification models found in the literature can be extended to a time-to-event setting without loss of performance, thus allowing a more comprehensive prediction of patient prognosis. Furthermore, explainability techniques proved to be key to reach a better understanding of the model and increase validation of its behaviour.